CD8A and cancer: Combining sICAM‐1 with anti‐PD‐1 enhanced the cancer cell‐killing activity of CD8+ T cells compared to treatment with sICAM‐1 or anti‐PD‐1 (25.2%: from 12.0% to 37.2%) (Figure 2f).